Upadacitinib superior to placebo in moderate-to-severe Crohn disease
For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of Medicine.
May 31, 2023
0
6